otcqb: OXIS

Immunotherapy for the Treatment of Cancer

Targeting multiple myeloma, triple-negative breast cancer, non-Hodgkin's lymphoma and more with highly potent biopharmaceutical drugs designed for targeted therapy.

View Product Pipeline


OXIS International, Inc., develops and commercializes innovative immunotherapeutic for the treatment of cancer and other unmet medical needs.

learn more


Antibody-drug conjugates are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of cancer.

learn more

Latest News

Oxis Eliminates Debt In Restructuring Deal, Will Move Forward With Phase 1/Phase 2 Clinical Trial Of Cancer Drug
Jan 11, 2016 • 8:30 EST | Read More

Oxis Biotech - University of Minnesota Masonic Cancer Center Receive FDA Allowance To Proceed With OXS-1550 (DT2219ARL) Phase 1 / Phase 2 Clinical Trial
Nov 23, 2015 • 8:00 EST | Read More


OXIS International Inc. OTCQB: OXIS
Loading... Change
Loading... Volume
Loading... 52 Week Range